Monday, December 11, 2017
business /
  • 2

Generic medicines hit Novartis profits

/ 05:05 PM July 18, 2017

A sign for Novartis International pharmaceutical company is seen on a building in Cambridge, Massachusetts, on March 18, 2017. AFP

Swiss drugmaker Novartis on Tuesday posted a drop in first half profits amid fierce competition for generic medicines and pricing pressures but said it was set to reach annual targets.

January-June net core income dropped 5 percent to $3.6 billion (3.1 billion euros), as overall first half sales dipped one percent to $23.7 billion, despite a six percent rise in volume, the group said.

Those volumes were buoyed by two medicines deemed to have strong potential — heart drug Entresto and Cosentyx, a treatment for psoriasis.


Stiff competition for generic medicine — not least copy cat drugs for its blockbuster cancer drug Gleevec — has eaten away some 3 percent of current profit margins, while price pressures have accounted for another 2 percent.

For the outlook for the year as a whole Novartis reconfirmed its objectives in saying it expected global sales this year to hit similar levels to 2016.

In January, the group announced total sales of $48.5 billion for 2016.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: Business, Earnings, novartis, pharmaceuticals, Switzerland
For feedback, complaints, or inquiries, contact us.

© Copyright 1997-2016 | All Rights Reserved